Add Company
Join Now

Aviragen Therapeutics Revenue and Competitors

License our Company Data API

Atlanta, GA USA

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • Aviragen Therapeutics's estimated annual revenue is currently $3.2M per year.(i)
  • Aviragen Therapeutics's estimated revenue per employee is $90,926

Employee Data

  • Aviragen Therapeutics has 35 Employees.(i)
  • Aviragen Therapeutics grew their employee count by -3% last year.

Aviragen Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M15-12%N/AN/A
#2
$3.5M6563%N/AN/A
#3
$3.2M35-3%N/AN/A
#4
$3.5M43N/AN/AN/A
#5
$3.6M422%N/AN/A
#6
$2M2912%N/AN/A
#7
$22.8M183-3%N/AN/A
#8
$0.2M4N/AN/AN/A
#9
$3.1M389%N/AN/A
#10
$1M2131%N/AN/A
Add Company

What Is Aviragen Therapeutics?

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11.

keywords:N/A

N/A

Total Funding

35

Number of Employees

$3.2M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.1M350%N/A
#2
$3.4M3552%N/A
#3
N/A3540%N/A
#4
$7.4M3521%N/A
#5
$4.1M35-20%N/A